Bluefin Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Bluefin Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-35,000	Closed	-$251K	–	305
2023 Q3	$251K	Buy	+35,000	New	+$3.96M	0.02%	93
2016 Q4	–	Sell	-76,600	Closed	-$2.35M	–	601
2016 Q3	$2.35M	Buy	+76,600	New	+$2.32M	0.09%	65
2016 Q2	–	Sell	-151,500	Closed	-$470K	–	596
2016 Q1	$470K	Buy	+151,500	New	+$2.65M	0.05%	191
2014 Q4	–	Sell	-50,000	Closed	-$83K	–	888
2014 Q3	$83K	Buy	+50,000	New	+$1.13M	﹤0.01%	694

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Bluefin Capital Management's SRPT Position: Q4 2023 in Review

Bluefin Capital Management sold out of Sarepta Therapeutics (SRPT) in Q4 2023, closing a stake of 13,015 shares — an estimated $1.58M sold.

Bluefin Capital Management first reported a position in SRPT in Q3 2014 and held it in 3 quarters. The position peaked at $1.58M in Q3 2023. 396 funds tracked by Wall St. Rank hold SRPT as of Q4 2023.

Bluefin Capital Management reported no remaining Sarepta Therapeutics position as of Q4 2023 after selling out during the quarter.
Bluefin Capital Management sold 13,015 Sarepta Therapeutics shares in Q4 2023, an estimated $1.58M.
Bluefin Capital Management first reported a position in Sarepta Therapeutics in Q3 2014 and held it in 3 quarters.
Bluefin Capital Management's Sarepta Therapeutics position peaked at $1.58M in Q3 2023.
396 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2023.

Based on Bluefin Capital Management's 13F filing for Q4 2023, filed 16 Feb 2024.